Lip GYH - Search Results

1

Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry.

Malavasi VL, Vitolo M, Proietti M, Diemberger I, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Kalarus Z, Tavazzi L, Maggioni AP, Lane DA, Lip GYH, Boriani G; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Malavasi VL, et al. Among authors: lip gyh. Eur J Clin Invest. 2022 Jul;52(7):e13773. doi: 10.1111/eci.13773. Epub 2022 Mar 28. Eur J Clin Invest. 2022. PMID: 35305020

2

A comparison of cardiovascular risk factors among Indo-Asian and caucasian patients admitted with acute myocardial infarction in Kuala Lumpur, Malaysia and Birmingham, England.

Dhanjal TS, Lal M, Haynes R, Lip G. Dhanjal TS, et al. Int J Clin Pract. 2001 Dec;55(10):665-8. Int J Clin Pract. 2001. PMID: 11777289

3

Tackling malignant hypertension: not so desperate now.

Felmeden DC, Beevers DG, Lip GY. Felmeden DC, et al. Am Heart J. 2002 Aug;144(2):E4. doi: 10.1067/mhj.2002.111542. Am Heart J. 2002. PMID: 12177662 No abstract available.

4

Do protein Z levels influence the prothrombotic state in atrial fibrillation?

Marco P, Marín F, García A, Roldán V, Lip GY. Marco P, et al. Thromb Res. 2002 May 15;106(4-5):269-70. doi: 10.1016/s0049-3848(02)00142-1. Thromb Res. 2002. PMID: 12297137 No abstract available.

5

Angiogenesis: basic pathophysiology and implications for disease.

Felmeden DC, Blann AD, Lip GY. Felmeden DC, et al. Eur Heart J. 2003 Apr;24(7):586-603. doi: 10.1016/s0195-668x(02)00635-8. Eur Heart J. 2003. PMID: 12657217 Review. No abstract available.

6

Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?

Marín F, Roldán V, Climent V, Garcia A, Marco P, Lip GY. Marín F, et al. Stroke. 2003 May;34(5):1181-6. doi: 10.1161/01.STR.0000065431.76788.D9. Epub 2003 Mar 27. Stroke. 2003. PMID: 12663879

7

Fibrinolytic function and atrial fibrillation.

Marín F, Roldán V, Lip GY. Marín F, et al. Thromb Res. 2003 Mar 15;109(5-6):233-40. doi: 10.1016/s0049-3848(03)00259-7. Thromb Res. 2003. PMID: 12818244 Review.

8

A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.

Felmeden DC, Blann AD, Spencer CG, Beevers DG, Lip GY. Felmeden DC, et al. Blood Coagul Fibrinolysis. 2003 Jul;14(5):425-31. doi: 10.1097/00001721-200307000-00001. Blood Coagul Fibrinolysis. 2003. PMID: 12851527 Clinical Trial.

9

Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation.

Roldán V, Marín F, Blann AD, García A, Marco P, Sogorb F, Lip GY. Roldán V, et al. Eur Heart J. 2003 Jul;24(14):1373-80. doi: 10.1016/s0195-668x(03)00239-2. Eur Heart J. 2003. PMID: 12871695

10

Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure.

Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY. Chin BS, et al. Eur J Clin Invest. 2003 Nov;33(11):941-8. doi: 10.1046/j.1365-2362.2003.01252.x. Eur J Clin Invest. 2003. PMID: 14636296

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,440 results

Search Page